Introduction
============

Exsanguination due to uncontrolled bleeding is the leading cause of potentially preventable deaths among trauma patients \[[@B1]-[@B3]\]. Upon arrival at the hospital, about one third of all trauma patients present with coagulopathy \[[@B4]-[@B6]\], which is associated with increased transfusion requirements, development of multi organ failure and death \[[@B5]-[@B7]\]. The presence of coagulopathy will aggravate active hemorrhaging in traumatized patients.

Coagulopathy associated with traumatic injury has historically been described as the result of multiple environmental factors such as acidemia and hypothermia, which have been shown to independently impair blood clotting \[[@B4],[@B7],[@B8]\]. Combined with dilution and consumption of coagulation factors and platelets secondary to fluid administration and bleeding, severe coagulopathy ensues \[[@B5],[@B7]\]. Recently, an early acute traumatic coagulopathy induced by the trauma and hypoperfusion, leading to up-regulation of thrombomodulin and causing the activation of systemic anticoagulant and fibrinolytic pathways, has been described \[[@B7]\].

Early monitoring of coagulation is essential to identify coagulopathy and this is routinely based on conventional plasma based coagulation tests such as prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), fibrinogen and platelet number \[[@B3]\]. These plasma-based tests only reflect the initiation of the hemostatic process \[[@B9]\] and they cannot be used for evaluating the amplification of propagation parts or increased fibrinolysis \[[@B7]\]. Thrombelastography (TEG)/thrombelastometry (ROTEM) analyses the viscoelastic properties of whole blood, thereby reflecting the entire hemostatic process. TEG therefore allows evaluation of coagulation in whole blood and comprises a more qualitative analysis of the individual cellular components and their interactions \[[@B10]-[@B12]\]. Viscoelastic hemostatic assays such as TEG are currently recommended by several international guidelines and teaching books concerning massive transfusion in trauma \[[@B3],[@B13],[@B14]\]. Furthermore, TEG is the only test available for rapid identification of hyperfibrinolysis, which is associated with increased mortality in trauma patients \[[@B15]-[@B17]\]. A schematic TEG trace is shown in Figure [1](#F1){ref-type="fig"}. In TEG, the hemostatic process is described by several measurements: R (reaction) time is the period from the beginning of the test until clot formation begins. α-angle reflects the increase in clot strength over time, and the maximal amplitude (MA) is a direct measure of the highest point on the TEG curve, representing maximal clot strength. Ly30 is a measurement of the fibrinolytic activity during the first 30 minutes after MA. MA is influenced primarily by platelet concentration and function \[[@B10],[@B11]\]. Low MA has been reported to be the best TEG indicator of increased transfusion requirements and mortality \[[@B18],[@B19]\]. Transfusion therapy guided by TEG has been shown to reduce peri- and postoperative bleeding and transfusion requirements, thereby improving survival rates for massively bleeding patients \[[@B20]\].

![**Thrombelastographic analysis with measured parameters**. Reaction time (R). Alpha angle (α), maximal amplitude (MA), lysis (LY).](1757-7241-19-52-1){#F1}

In trauma, TEG has been described as a better predictor of transfusion requirements than PT, INR or APTT \[[@B18]\] and recently, initial experiences with TEG-guided management of life-threatening post-injury coagulopathy was reported by Kashuk and colleagues with a favourable outcome when comparing with historic controls \[[@B21]\]. These results align with Schöchl et al. who found a beneficial effect of goal-directed resuscitation in actively bleeding trauma patients when juxtaposed to the patient outcome predicted by trauma and injury severity score (TRISS) \[[@B22]\]. With the consistent findings that low clot strength is associated with poor outcome in trauma patients \[[@B15],[@B18]\], this end-point together with transfusion requirements have been chosen in the present study concerning patients suffering major trauma.

Methods
=======

A retrospective study including trauma patients from 2006 and 2007, who were admitted at the Trauma Centre at Rigshospitalet, Copenhagen. The inclusion criteria were: The patients should be included in the European Trauma Audit and Research Network (TARN) \[[@B23],[@B24]\], and have a TEG analysis performed along with the initial blood tests sampled upon arrival at the hospital, which occurs before any blood products are administered. TARN is a joint European database containing uniform reports on all included trauma patients. Only including patients with severe traumatic injuries, this database provides access to comparable patient data in the specified time period. Data was collected using several databases. Gender and age were registered using the Danish civil registration numbers. A review of patient charts and TARN-records revealed mechanism and type of traumatic injury and Injury Severity Score (ISS) \[[@B23],[@B25]\]. TEG was performed in the blood bank on citrated blood samples within 5-7 min of blood sampling in accordance with our previously published experience \[[@B26]\]. The TEG analysis was displayed in real-time in the trauma center allowing for immediate interpretation and intervention as described elsewhere \[[@B27]\]. TEG (TEG 5000, Haemoscope, Niles, IL) parameters of R-time, α-angle and maximal amplitude (MA) and laboratory parameters such as hemoglobin and platelet count (Sysmex 2100, Sysmex Corp., Kobe, Japan), APTT and INR (ACL TOP, Beckman Coulter Inc., Brea, CA), lactate and blood glucose (Modular P-modul, Hitachi, Tokyo, Japan) including the number and time for delivery of packed red blood cells (RBC), fresh frozen plasma (FFP) and platelet concentrates (PC) were collected using the Regional Blood Bank Database. Data on hospital length of stay and 30-day mortality was collected using the hospital registration system.

Patients were categorized as having reduced clot strength if MA was lower than the cut-off value supplied from the manufacturer at time of analysis, MA \< 50 mm.

Statistics
----------

Distributions of data were inspected using probability plots, and non-normal distributed variables were log-transformed. Data on patients stratified according to MA \< 50 mm were compared by student-T test. Associations of mortality and MA \< 50 mm, APTT, blood glucose, hemoglobin, blood lactate, INR or platelet counts were analyzed by multivariable regression including co-variables of age and ISS, using 30-day mortality (yes/no) as dependent variable. Values are presented as means with 95% Confidence Intervals and results of multivariable regression analyses are presented as Odds Ratio (OR) with X^2^. Area under the curve (AUC) using Receiver Operating Characteristic (ROC) was calculated to compare relative prognostic efficiency for 30-day mortality on each assay. P-values \< 0.05 were considered significant. Statistical calculations were performed using SPSS 17 (IBM Corp., Somers, NY).

Results
=======

Demographics of the 89 included patients are presented in Table [1](#T1){ref-type="table"}. The vast majority presented with blunt injuries, and 65 out of the 89 patients suffered injuries relating to traffic accidents. The mean ISS of the cohort was 21 and the 30-day mortality was 17%.

###### 

Patient demographics (*n*= 89)

  Age (years)             39 (35-43)
  ----------------------- -----------------
  Males                   59 (66%)
                          
  Blunt trauma            76 (85%)
                          
  Cause of trauma         
                          
   Traffic accident       65
                          
   Fall from heights      10
                          
   Assault                10
                          
   Suicide attempt        4
                          
  Type of trauma          
                          
   Thoracic               15
                          
   Abdominal              7
                          
   Extremities            4
                          
   Cerebral               18
                          
   Multi trauma           37
                          
   Other                  8
                          
  Injury Severity Score   21 (19-23)
                          
  Transfusions in units   
                          
   RBC                    3.4 (2.6-4.4)
                          
   FFP                    2.2 (1.7-2.8)
                          
   PC                     1.6 (1.4-1.9)
                          
  Length of stay (days)   10.3 (8.1-13.1)
                          
  Thirty-day mortality    15 (17%)

Demographics of the 89 patients included in the study. Frequencies are stated as count with percentage in parenthesis. Age, Injury Severity Score, blood product transfusions and length of stay are stated as means with 95% Confidence Intervals. Packed red blood cells (RBC), fresh frozen plasma (FFP) and platelet concentrates (PC).

Patients with reduced clot strength presented with higher ISS 27 (95% CI, 20-34) vs. 19 (95% CI, 17-22), p = 0.006 than the rest of the cohort.

With regards to standard laboratory parameters, hemoglobin and platelet counts were lower in patients with low clot strength compared to the rest of the cohort \[9.7 (95% CI 8.5-10.7) vs. 11.9 (95% CI, 11.5-12.4) g/dL, p \< 0.001 and 140 (95% CI, 112-168) vs. 214 (95% CI, 196-231) × 10^9^/L, p \< 0.001, respectively\]. APTT and INR were higher in patients with reduced clot strength when compared to the rest of the cohort \[49 (95% CI, 37-66) vs. 29 (95% CI, 27-30) seconds, p \< 0.001 and 1.4 (95% CI, 1.3-1.5) vs. 1.2 (95% CI, 1.1-1.2) arbitrary units, p \< 0.001, respectively\]. Glucose was also higher in patients with low clot strength \[10.3 (95% CI, 8.7-12.1) vs. 7.7 (95% CI, 7.2-8.3) mmol/L, p = 0.001\].

During the first 24 hours of admission, patients with reduced clot strength received approximately twice as many blood products compared with the rest of the cohort (Table [2](#T2){ref-type="table"}), and there was a significant correlation between clot strength and the amount of transfused RBC (p = 0.01), FFP (p = 0.04), and PC (p = 0.03). Patients presenting with low clot strength demonstrated increased 30-day mortality (47% vs. 10%, p \< 0.001). In patients with low clot strength, 7 out of 8 patients expired within the first 48 hours from hospital admission (Figure [2](#F2){ref-type="fig"}).

###### 

Patients stratified according to clot strength

  ------------------------------------------------------------------------------------------
                              Low clot strength\   Normal or high clot strength\   p-value
                              *n = 17*             *n = 72*                        
  --------------------------- -------------------- ------------------------------- ---------
  Age (years)                 43 (32-54)           38 (34-43)                      0.38

                                                                                   

  Males                       10 (59%)             49 (68%)                        0.47

                                                                                   

  Blunt trauma                16 (94%)             60 (83%)                        0.45

                                                                                   

  Type of trauma                                                                   0.66

                                                                                   

   Thoracic                   1                    14                              

                                                                                   

   Abdominal                  1                    6                               

                                                                                   

   Extremities                0                    4                               

                                                                                   

   Cerebral                   5                    13                              

                                                                                   

   Multi trauma               8                    29                              

                                                                                   

   Other                      2                    6                               

                                                                                   

  Injury Severity Score       27 (20-34)           19 (17-22)                      0.006

                                                                                   

  Laboratory analyses                                                              

                                                                                   

   Hemoglobin (g/dL)          9.7 (8.5-10.7)       11.9 (11.5-12.4)                \<0.001

                                                                                   

   Platelet count (10^9^/L)   140 (112-168)        214 (196-231)                   \<0.001

                                                                                   

   APTT (seconds)             49 (37-66)           29 (27-30)                      \<0.001

                                                                                   

   INR (arbitrary units)      1.4 (1.3-1.5)        1.2 (1.1-1.2)                   \<0.001

                                                                                   

   Glucose (mmol/L)           10.3 (8.7-12.1)      7.7 (7.2-8.3)                   0.001

                                                                                   

   Lactate (mmol/L)           3.3 (2.4-4.6)        2.5 (2.1-2.9)                   0.11

                                                                                   

  TEG                                                                              

                                                                                   

   R (minutes)                6.3 (5.2-7.4)        5.2 (4.9-5.5)                   0.01

                                                                                   

   Angle (degrees)            47 (40-53)           65 (63-67)                      0.001

                                                                                   

   MA (mm)                    39 (34-44)           60 (59-61)                      N/A

                                                                                   

   Ly30 (%)                   0.8 (0.0-1.7)        0.7 (0.5-0.9)                   0.58

                                                                                   

  Transfusions in units                                                            

                                                                                   

   RBC                        6.4 (3.7-11.2)       2.9 (2.2-3.8)                   0.02

                                                                                   

   FFP                        3.6 (1.9-6.6)        2.0 (1.5-2.6)                   0.06

                                                                                   

   PC                         2.3 (1.5-3.6)        1.5 (1.2-1.7)                   0.04

                                                                                   

  Length of stay (days)       4.9 (2.7-8.7)        12.3 (9.6-15.7)                 0.002
  ------------------------------------------------------------------------------------------

Data of patients with low clot strength (maximal amplitude \< 50 mm) compared to patients with normal or high clot strength (maximal amplitude ≥ 50 mm). Frequencies are stated as count with percentage in parenthesis. Age, laboratory and thrombelastographic (TEG) analyses, blood product transfusions, Injury Severity Score and length of stay are stated as means with 95% Confidence Intervals. Activated partial thromboplastin time (APTT), international normalized ratio (INR), packed red blood cells (RBC), fresh frozen plasma (FFP), platelet concentrates (PC).

![**Mortality in patients with low vs. non-low clot strength**.](1757-7241-19-52-2){#F2}

By logistic regression analysis with 30-day mortality as endpoint, reduced clot strength was an independent predictor of increased mortality after adjusting for age and ISS (Table [3](#T3){ref-type="table"}).

###### 

Prediction of mortality by low clot strength, age and Injury Severity Score

                                                       OR     95% CI         p-value   X^2^
  ---------------------------------------------------- ------ -------------- --------- ------
  Injury Severity Score (per point)                    1.09   (1.01-1.16)    0.02      6.6
                                                                                       
  Age (per year)                                       1.03   (1.00-1.06)    0.09      3.0
                                                                                       
  Low clot strength (maximal clot strength \< 50 mm)   5.00   (1.22-20.45)   0.03      4.8

Multivariable analysis of age, Injury Severity Score and low clot strength (maximal amplitude \< 50 mm) with 30-day mortality as dependent variable.

Likewise, APTT (OR = 1.1 (95% CI, 1.0-1.2), chi-square = 18.8, p = 0.008), glucose (OR = 1.4 (95% CI, 1.1-1.8), chi-square = 15.6, p = 0.002) and lactate (OR = 1.4 (95% CI, 1.1-1.9), chi-square = 8.5, p = 0.007) were also associated with 30-day mortality after adjusting for age and ISS.

Relative prognostic efficiency for 30-day mortality using ROC AUC was for APTT 0.78 (95% CI, 0.61-0.95) p \< 0.001, for INR 0.63 (95% CI, 0.44-0.81) p = 0.13 and for MA 0.70 (95% CI, 0.53-0.86) p = 0.02 (Figure [3](#F3){ref-type="fig"}).

![**ROC curves for APTT, INR and MA in relation to mortality**. Activated partial thromboplastin time (APTT), international normalized ratio (INR), maximal amplitude (MA).](1757-7241-19-52-3){#F3}

Only one patient presented with pathologically increased fibrinolysis, 54% (normal \< 8%). This patient also demonstrated reduced clot strength, had the highest ISS in the cohort (66) and expired on the day of admission.

Discussion
==========

The main finding of the present study was that low clot strength evaluated by TEG was independently associated with increased mortality at 30-days post trauma, also after adjusting for ISS and age. To our knowledge, this is the first study reporting of an independent association between reduced clot strength upon admission and 30-day mortality in trauma patients. Recently, Kashuk et al. found a similar association between low clot strength and 24-hour survival in trauma patients \[[@B21]\]. Our results correspond to the findings of Carroll et al., who in 161 trauma patients found that non-survivors presented with significantly lower clot strength compared to survivors \[[@B15]\]. Abnormally reduced clot strength has also previously been reported to be associated with increased 30-day mortality in patients admitted to the intensive care unit, reflecting the clinical significance of whole blood viscoelastic hemostatic assays such as TEG in critically ill patients \[[@B19]\]. The association between reduced clot strength upon hospital admission, increased transfusion requirements and high 30-day mortality may reflect that patients with reduced clot strength more frequently develop life-threatening bleedings and thereby experience more episodes of hypoperfusion. This is indicated by the increased lactate in these patients when compared to those with normal clot strength. Consequently, normalizing hemostasis in these patients may improve outcome. In alignment with this, we have previously demonstrated that early aggressive administration of plasma and platelets in addition to RBC can reverse the acute coagulopathy of trauma found by TEG \[[@B26]\]. This transfusion strategy reduces mortality in massively bleeding patients \[[@B20]\], indicating that goal-directed therapy based on TEG may improve outcome. This corresponds to the findings of Kashuk et al., who reported that using TEG for management of life-threatening postinjury coagulopathy was associated with a favourable outcome when compared to historic controls \[[@B21]\].

An independent association between APTT and 30-day mortality aligns well with the findings of Brohi et al. and Macleod et al. who reported that a substantial proportion of trauma patients upon admission presented with coagulopathy unrelated to resuscitation fluids and hypothermia, and that this was associated with a 3-4 fold increased mortality \[[@B4],[@B6]\]. Interestingly, plasma based coagulation assays have consistently been shown not to correlate to relevant clinical bleeding conditions \[[@B28]\] and consequently, in trauma patients, mild prolongation of APTT and/or INR must reflect something else of relevance for outcome in these severely injured patients. In the present study, APTT demonstrated the best ROC characteristics with regard to mortality, and we speculate that this reflects the degree of endothelial breakdown \[[@B29]\]. Supporting this, we recently found that severely injured trauma patients presented with increased glycocalyx and endothelial breakdown, evaluated by syndecan-1 and soluble thrombomodulin (sTM) in plasma, respectively. Constituents of the glycocalyx such as heparansulphate and syndecan-1 together with endothelial sTM all have potent anticoagulant properties, and this may be reflected by increased APTT \[[@B30]\].

Brohi and coworkers coined the term ACoTS to describe this acute coagulopathy of trauma \[[@B31]\]. It has been postulated that the most important factors leading to this condition are tissue injury and shock, and that the coagulopathy identified by increased APTT and PT is a result of activation of the protein C system together with increased fibrinolysis \[[@B32]\]. The importance of tissue hypoperfusion for outcome of trauma patients, as suggested by Brohi et al. \[[@B7]\], corresponds well with our finding of lactate being independently associated with 30-day mortality also after adjusting for ISS and age. The relevance of blood lactate for mortality in trauma patients was recently reported by Vandromme et al. \[[@B33]\]. When comparing patients with reduced clot strength to the rest of the cohort, the hypocoagulable patients were more seriously injured as reflected by a higher ISS. Carroll et al. and Kaufmann et al. also reported that trauma patients with evidence of TEG hypocoagulability had higher ISS than those presenting with normal or hypercoagulable TEG profiles \[[@B15],[@B34]\]. The hypocoagulable TEG may reflect increased consumption of coagulation factors and platelets secondary to the trauma, thus displaying disseminated intravascular coagulation (DIC) with a hemorrhagic phenotype \[[@B35]\] or, as discussed previously, ACoTS \[[@B7]\], or perhaps a combination. The standard coagulation analyses such as APTT and INR were prolonged in TEG hypocoagulable patients, and this may be ascribed to both DIC with a hemorrhagic phenotype and ACoTS, whereas the reduced platelet count in hypocoagulable patients might indicate a consumptive state.

Hyperfibrinolysis has been reported to be an integral part of the coagulopathy of trauma \[[@B36]\] and Schöchl et al. has reported that this condition is observed in the most seriously injured patients, and is associated with elevated mortality \[[@B16]\]. This corresponds to the findings of the present study, where only the patient with the highest ISS of the entire cohort presented with increased fibrinolysis.

In the present study, patients with hypocoagulable TEG received twice as many blood product transfusions during the first 24 hours of admission than the rest of the cohort. A significant correlation between clot strength and the amount of transfused RBC, FFP and PC was found. Plotkin et al. reported that in combat trauma patients, thrombelastography was a more accurate indicator of blood product requirements than PT, APTT and INR \[[@B18]\]. Furthermore, Kaufmann et al. found that only ISS and TEG were predictive of transfusions, whereas PT and APTT were not \[[@B34]\]. The superiority of TEG in identifying clinically relevant coagulopathies and blood product requirements can be explained by the introduction of the cell-based model of hemostasis. This emphasizes the role of platelets for intact thrombin generation and highlights the importance of the dynamics in thrombin generation, which affect the quality and stability of the thrombus formed \[[@B37]\]. Consequently, hemostatic assays performed on plasma such as APTT and PT are of limited value \[[@B38]\] and do not correlate with clinically relevant coagulopathies or bleeding conditions \[[@B28]\]. To date, more than 25 studies including more than 4,500 patients have evaluated TEG versus conventional coagulation assays on bleeding and transfusion requirements in surgical patients undergoing cardiac, liver, vascular or trauma surgery and in patients requiring massive transfusion. These studies all report that whole blood TEG is superior in predicting the need for blood transfusion, and that treatment based on the results of the TEG analysis reduces transfusion requirements and the need for re-do surgery in contrast to treatments relying on plasma based coagulation assays \[[@B11]\]. Early identification and institution of goal-directed treatment of post-traumatic coagulopathy could, potentially, improve outcome in trauma patients as indicated in the studies performed by Kashuk et al. and Schöchl et al. \[[@B21],[@B22]\].

Our results are subject to limitations inherent to observational studies and thereby do not allow independent estimation of the cause-and-effect relationship between the TEG results and outcome. The results of this study indicate an association rather than a correlation between low clot strength and mortality post-trauma. Furthermore, this is a retrospective study, which was conducted in a limited number of patients at a single centre and, although internal validity is high, external validity may be limited. Another limitation of the present study is, that the reported changes of TEG parameters had to be interpreted on the basis of external reference values. The clinical inhibitory effect of antithrombotic medications such as clopidogrel and aspirin on platelet aggregation cannot be assessed using hemostatic assays, because the assay activators cancel this inhibition. Nor will conditions affecting the endothelium such as von Willebrand disease be detected by hemostatic assays \[[@B11]\].

Conclusions
===========

Low clot strength in trauma patients, evaluated by TEG upon admission to the trauma centre is independently associated with increased 30-day mortality, even after adjusting for age and ISS. We believe that targeted interventions with plasma and platelets in addition to RBC together with antifibrinolytic therapy, based on the results of the TEG analysis, may improve outcome in trauma patients. Prospective randomized trials investigating this potential are highly warranted.
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